Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

Hepatology

Volumn 54, Issue 1, 2011, Pages 328-343

  Bacon, Bruce R ^a   Adams, Paul C ^b   Kowdley, Kris V ^c   Powell, Lawrie W ^d   Tavill, Anthony S ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; HEPCIDIN; HFE PROTEIN; IRON;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; CANCER EPIDEMIOLOGY; DIABETES MELLITUS; FERRITIN BLOOD LEVEL; GYNECOMASTIA; HEART FAILURE; HEMOCHROMATOSIS; HEPATOMEGALY; HUMAN; IMPOTENCE; INTESTINE ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LETHARGY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; MASS SCREENING; MEDICAL LITERATURE; PATHOPHYSIOLOGY; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING TEST; SKIN PIGMENTATION; SPLENOMEGALY; TESTIS ATROPHY; WEAKNESS;

BIOPSY; FERRITINS; GENETIC TESTING; HEMOCHROMATOSIS; HUMANS; IRON; LIVER; LIVER DISEASES; UNITED STATES;

EID: 79959547265     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24330     Document Type: Article

References (95)

1. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines: The Explicit Approach. Philadelphia, PA: American College of Physicians; 1992.
2. American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925-926.
3. American College of Cardiology/American Heart Association. Methodology Manual for ACC-AHA Guideline Writing Committees: Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines, April 2006.
4. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493-498.
5. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149: 270-272.
6. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778.
7. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
8. Pietrangelo A. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3-22.
9. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39: 21-29.
10. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
11. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelønning K, Fjøsne U, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65, 238 persons. Scand J Gastroenterol 2001; 36: 1108-1115.
12. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
13. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485-504.
14. Pietrangelo A. Juvenile hemochromatosis. J Hepatol 2006; 45: 892-894.
15. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dubé MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
16. Camaschella C, Roetto A, Calì A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
17. Pietrangelo A. Non-HFE hemochromatosis. Semin Liver Dis 2005; 25: 450-460.
18. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008; 48: 991-1001.
19. Gordeuk VR. African iron overload. Semin Hematol 2002; 39: 263-269.
20. Bottomley SS. Secondary iron overload disorders. Semin Hematol 1998; 35: 77-86.
21. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27: 243-250.
22. Whitington PF, Hibbard JU. High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 2004; 364: 1690-1698.
23. Waheed A, Parkkila S, Saarnio J, Fleming RE, Zhou XY, Tomatsu S, et al. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci U S A 1999; 96: 1579-1584.
24. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis. Clin Liver Dis 2004; 8: 755-773.
25. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
26. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
27. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487.
28. Ganz T. Iron homeostasis: fitting the puzzle pieces together. Cell Metab 2008; 7: 288-290.
29. Fleming RE, Britton RS. Iron Imports. VI. HFE and regulation of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol 2006; 290: G590-G594.
30. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006; 281: 28494-28498.
31. Fleming RE, Bacon BR. Orchestration of iron homeostasis. N Engl J Med 2005; 352: 1741-1744.
32. Philippe MA, Ruddell RG, Ramm GA. Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol 2007; 13: 4746-4754.
33. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest 1983; 71: 429-439.
34. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990; 11: 127-137.
35. Olynyk JK, Britton RS, Stephenson AH, Leicester KL, O'Neill R, Bacon BR. An in vitro model for the study of phagocytosis of damaged hepatocytes by rat Kupffer cells. Liver 1999; 19: 418-422.
36. Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. Homozygosity for hemochromatosis: clinical manifestations. Ann Intern Med 1980; 93: 519-525.
37. Milder MS, Cook JD, Stray S, Finch CA. Idiopathic hemochromatosis, an interim report. Medicine (Baltimore) 1980; 59: 34-49.
38. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-1262.
39. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991; 90: 445-449.
40. Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92: 784-789.
41. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166: 294-301.
42. Adams PC. Hemochromatosis case definition: out of focus? Nat Clin Pract Gastroenterol Hepatol 2006; 3: 178-179.
43. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120: 999.e1-e7.
44. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-1328.
45. Bassett ML, Halliday JW, Ferris RA, Powell LW. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984; 87: 628-633.
46. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-1301.
47. Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-936.
48. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953-962.
49. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-633.
50. Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002; 36: 673-678.
51. Adams PC. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet 1998; 53: 176-178.
52. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002; 122: 646-651.
53. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529-1535.
54. Jacobs EM, Hendriks JC, Marx JJ, van Deursen CT, Kreeftenberg HG, de Vries RA, et al. Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS). Neth J Med 2007; 65: 425-433.
55. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938.
56. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
57. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122: 281-289.
58. Olynyk JK, O'Neill R, Britton RS, Bacon BR. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications. Gastroenterology 1994; 106: 674-677.
59. Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis 2005; 25: 392-401.
60. Deugnier Y, Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 2007; 13: 4755-4760.
61. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-29.
62. Kowdley KV, Trainer TD, Saltzman JR, Pedrosa M, Krawitt EL, Knox TA, et al. Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. Gastroenterology 1997; 113: 1270-1277.
63. Summers KM, Halliday JW, Powell LW. Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index. Hepatology 1990; 12: 20-25.
64. Sallie RW, Reed WD, Shilkin KB. Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis. Gut 1991; 32: 207-210.
65. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991; 101: 368-372.
66. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-1119.
67. Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44: 472-477.
68. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 162-166.
69. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127( 5 Suppl 1): S79-S86.
70. Brittenham GM, Klein HG, Kushner JP, Ajioka RS. Preserving the national blood supply. Hematology Am Soc Hematol Educ Program 2001: 422-432.
71. Lynch SR, Cook JD. Interaction of vitamin C and iron. Ann N Y Acad Sci 1980; 355: 32-44.
72. Ashrafian H. Hepcidin: the missing link between hemochromatosis and infections. Infect Immun 2003; 71: 6693-6700.
73. Poulos JE, Bacon BR. Liver transplantation for hereditary hemochromatosis. Dig Dis 1996; 14: 316-322.
74. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129: 494-503.
75. Farrell FJ, Nguyen M, Woodley S, Imperial JC, Garcia-Kennedy R, Man K, et al. Outcome of liver transplantation in patients with hemochromatosis. Hepatology 1994; 20: 404-410.
76. Yu L, Ioannou GN. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 2007; 133: 489-495.
77. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30: 137-144.
78. Franchini M, Targher G, Capra F, Montagnana M, Lippi G. The effect of iron depletion on chronic hepatitis C virus infection. Hepatol Int 2008; 2: 335-340.
79. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-939.
80. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-1258.
81. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341: 99-109.
82. Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010; 52: 1671-1779.
83. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.
84. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42: 81-85.
85. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-19.
86. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861.
87. Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009; 113: 4853-4855.
88. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327-331.
89. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
90. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
91. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999; 94: 1593-1600.
92. Tavill AS. Screening for hemochromatosis: phenotyping or genotyping or both? Am J Gastroenterol 1999; 94: 1430-1433.
93. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-2919.
94. Hall MA, Barton JC, Adams PC, McLaren CE, Reiss JA, Castro O, et al. Genetic screening for iron overload: no evidence of discrimination at 1 year. J Fam Pract 2007; 56: 829-834.
95. Adams P, Barton JC, McLaren GD, Acton RT, Speechley M, McLaren CE, et al. Screening for iron overload: lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) Study. Can J Gastroenterol 2009; 23: 769-772.